Milo Biotechnology
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Milo Biotechnology
Novartis Swaps Two AveXis Executives For One Following Zolgensma Data Manipulation
The big pharma could not confirm whether AveXis co-founder and CSO Brian Kaspar and his brother, SVP of R&D Allan Kaspar, were fired. Instead, Novartis noted that the withholding of preclinical safety data for Zolgensma was limited to the action of a few employees. NIBR preclinical safety chief takes key role at AveXis
Pfizer’s DMD Setback With Domagrozumab Shifts Focus To Gene Therapy Approach
With its first AAV gene therapy candidate from Bamboo Therapeutics expected to report data in 2019, Pfizer’s efforts to get in the DMD competition now center on that modality.
Emergings In Brief, May 2012
Brief profiles of these recently formed companies: Abionic, Alcresta, Avenir Medical and Milo Biotechnology.
Out Of The Blocks, May 2012
Brief profiles of these recently formed companies: Abionic, Alcresta, Avenir Medical, Avion Pharmaceuticals, Ground Fluor Pharmaceuticals and Milo Biotechnology.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice